La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

PeptiDream Bilan de santé

Santé financière contrôle des critères 0/6

Informations clés

35.6%

Ratio d'endettement

JP¥20.93b

Dette

Ratio de couverture des intérêts	8112x
Argent liquide	JP¥25.48b
Fonds propres	JP¥58.77b
Total du passif	JP¥37.11b
Total des actifs	JP¥95.88b

Mises à jour récentes de la santé financière

Pas de mise à jour

Recent updates

PeptiDream Inc. Just Beat Revenue Estimates By 13%

Aug 12

PeptiDream Inc. (TSE:4587) Surges 27% Yet Its Low P/S Is No Reason For Excitement

Jun 30

News Flash: Analysts Just Made A Meaningful Upgrade To Their PeptiDream Inc. (TSE:4587) Forecasts

Jun 02

PeptiDream Bilan de santé

Santé financière contrôle des critères 0/6

Informations clés

Mises à jour récentes de la santé financière

Recent updates

PeptiDream Inc. Just Beat Revenue Estimates By 13%

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates fall by 11%

Consensus EPS estimates increase by 10%

Now 20% undervalued

Price target increased by 7.4% to JP¥3,060

PeptiDream Inc. (TSE:4587) Surges 27% Yet Its Low P/S Is No Reason For Excitement

National Cancer Center and PeptiDream Announces the First Dosing of Cu-PD-32766 in a patient with Clear Cell Renal Cell Carcinoma

PeptiDream Inc. to Report Q2, 2024 Results on Aug 08, 2024

News Flash: Analysts Just Made A Meaningful Upgrade To Their PeptiDream Inc. (TSE:4587) Forecasts

Consensus revenue estimates increase by 10%

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates fall by 15%, revenue upgraded

PeptiDream Inc.'s (TSE:4587) 42% Price Boost Is Out Of Tune With Revenues

Is PeptiDream Inc. (TSE:4587) Trading At A 46% Discount?

Insufficient new directors

PeptiDream Inc.'s (TSE:4587) 25% Jump Shows Its Popularity With Investors

PeptiDream Inc. to Report Q1, 2024 Results on May 14, 2024

Consensus EPS estimates fall by 17%

Full year 2023 earnings: EPS and revenues miss analyst expectations

PeptiDream Inc., Annual General Meeting, Mar 27, 2024

Now 21% undervalued

Investor sentiment improves as stock rises 16%

PeptiDream Inc. to Report Fiscal Year 2023 Results on Feb 14, 2024

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Price target decreased by 8.0% to JP¥2,817

New minor risk - Share price stability

New major risk - Revenue and earnings growth

PeptiDream Inc. to Report Q3, 2023 Results on Nov 09, 2023

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

New major risk - Revenue and earnings growth

Investor sentiment improves as stock rises 21%

PeptiDream Inc. to Report Q2, 2023 Results on Aug 09, 2023

Consensus EPS estimates increase by 11%

First quarter 2023 earnings: EPS misses analyst expectations

PeptiDream Inc. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2023

PeptiDream Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2023

Full year 2022 earnings: EPS exceeds analyst expectations

PeptiDream Inc., Annual General Meeting, Mar 29, 2023

Consensus EPS estimates increase by 25%

PeptiDream Inc. to Report Q4, 2022 Results on Feb 14, 2023

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Less than half of directors are independent

PeptiDream Inc. Provides Earnings Guidance for the Fiscal Year Ending December 31, 2022

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

PeptiDream Inc. Provides Consolidated Revenue Guidance for the Fiscal Year Ending December 31, 2022

Second quarter 2022 earnings released: JP¥1.75 loss per share (vs JP¥2.59 profit in 2Q 2021)

Price target decreased to JP¥3,300

PeptiDream Inc. to Report Q3, 2022 Results on Nov 10, 2022

Investor sentiment deteriorated over the past week

Price target decreased to JP¥3,586

First quarter 2022 earnings released: JP¥6.39 loss per share (vs JP¥3.43 profit in 1Q 2021)

PeptiDream Inc. Provides Consolidated Revenue Guidance for the Fiscal Year Ending December 31, 2022

Less than half of directors are independent

PeptiDream Inc. to Report Q1, 2022 Results on May 12, 2022

Investor sentiment deteriorated over the past week

Full year 2021 earnings: Revenues in line with analyst expectations

PeptiDream Inc. Provides Earnings Guidance for the Fiscal Year Ending December 31, 2022

PeptiDream Inc., Annual General Meeting, Mar 24, 2022

Price target decreased to JP¥4,413

Price target decreased to JP¥5,038

Third quarter 2021 earnings released: EPS JP¥19.97 (vs JP¥29.81 in 3Q 2020)

PeptiDream Inc. (TSE:4587) signed an agreement to acquire Radiopharmaceutical business of FUJIFILM Toyama Chemical Co., Ltd. from Fujifilm Corporation for ¥30.5 billion.

Full year 2020 earnings released: EPS JP¥35.40 (vs JP¥7.80 loss in FY 2019)

Chairman of the Board Kiichi Kubota has left the company

PeptiDream Inc. to Report Q2, 2021 Results on Aug 05, 2021

PeptiDream Inc. Announces Licensing of Automated PDPS Platform to Ono Pharmaceutical Co., Ltd

New 90-day low: JP¥5,070

Full year 2020 earnings released

PeptiDream Inc. Announces the Resignation of Kiichi Kubota from the Board of Directors

New 90-day high: JP¥6,440

New 90-day high: JP¥5,990

Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) completed the acquisition of remaining 58% stake in Kleo Pharmaceuticals, Inc from PeptiDream Inc. (TSE:4587) and others.

Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) entered into a merger agreement to acquire the remaining 58% stake in Kleo Pharmaceuticals, Inc from PeptiDream Inc. (TSE:4587) and others.

New 90-day high: JP¥5,730